NORGINE REINFORCES ITS COMMITMENT TO IMPROVING THE DETECTION OF COLORECTAL CANCER

Back to media releases
Next media release
04 March 2016

 

LONDON, UK, Friday 4 March 2016, 07:00 GMT. Norgine B.V. today announces that it is supporting the March 2016 European Colorectal Cancer awareness campaign. Colorectal cancer is the second most common cause of cancer-related mortality in the world1, with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe. 2,3
 

As a leader in bowel cleansing and colonoscopy, Norgine has been collaborating with key European patient organisations in order to increase the detection of colorectal cancer and to help improve patients’ quality of life. Norgine is a patient centric company and is supporting key organisations such as;
 

·         Alianza para la prevención del Cáncer de colon, Spain

·         Asociación de pacientes con síndrome de Lynch, Spain

·         Beating Bowel Cancer, UK

·         Bowel Cancer UK

·         Conseil National Professionnel d’Hépato-Gastroentérologie, France

·         Deutschland gegen Darmkrebs, Germany

·         Dutch Digestive Foundation, The Netherlands

·         Felix Burda Foundation, Germany

·         Selbsthilfgruppe Darmkrebs, Austria

·         Spanish Digestive Society Foundation, Spain

·         Stiftung LebensBlicke, Germany

·         Stop Darmkanker, Belgium
 

Over the years, Norgine has strengthened its colon cancer prevention and detection portfolio to ensure quality in colonoscopy and ultimately enhance health outcomes for patients.
 

Norigne’s bowel cleansing and colonoscopy portfolio includes KLEAN-PREP®, MOVIPREP® and ENDOCUFF VISION®.
 

Click here to view the full list of all organisations to whom Norgine provides support.

 

Ends

 

 

Notes to Editors:
 

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 317 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
 

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
 

For more information, please visit www.norgine.com
 

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
 

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

 

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine

 

Job code: GL/COR/0216/0061

March 2016

 

References

1 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al.  Cancer incidence and mortality patterns in Europe:  Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403

2 Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 3 March 2016]

3 Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915